Krantz–Borner disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Krantz–Borner Disease: Comprehensive Patient Guide

Krantz–Borner Disease (Acquired Ocular Myasthenia)

Overview

Krantz–Borner disease, also known as acquired ocular myasthenia or ocular myasthenia gravis (OMG), is an autoimmune disorder that selectively weakens the muscles that move the eyes and control the eyelids. Unlike generalized myasthenia gravis, which involves multiple muscle groups, Krantz–Borner disease is confined to the extra‑ocular muscles at onset. It is named after neurologists Harvey Krantz and Heinrich Börner**, who described the characteristic pattern of fluctuating ptosis and diplopia in the 1930s.

The disease can affect anyone, but it is most common in:

  • Women aged 20–40 years (female‑to‑male ratio ≈ 3:1 in this age group)
  • Men aged > 60 years (incidence rises in older males)

Overall prevalence of ocular myasthenia (including Krantz–Borner disease) is estimated at **15–20 per 100,000** people worldwide, representing roughly 15 % of all myasthenia gravis cases.1

Symptoms

Symptoms are usually **fluctuating**, worsening with activity and improving with rest. Common manifestations include:

  • Ptosis (drooping eyelid) – often unilateral at first, may become bilateral. The droop is more noticeable toward the end of the day.
  • Diplopia (double vision) – horizontal, vertical, or diagonal; typically worse when looking up or in the direction of the affected muscle.
  • Eye fatigue – a sensation of heaviness or “burning” after reading, computer work, or driving.
  • Difficulty focusing – especially after prolonged near‑task work.
  • Eye‑movement abnormalities – including:
    • Limited upward gaze (vertical diplopia)
    • Inability to look laterally (horizontal diplopia)
    • Oscillopsia (perception that the environment is moving) in severe cases.
  • Variable symptoms – symptoms may improve after a short nap, with exposure to cool air, or after the administration of anticholinesterase medication.

Rarely, patients may experience mild facial muscle weakness or dysphagia, which signals progression to generalized myasthenia gravis.

Causes and Risk Factors

Underlying Pathophysiology

Krantz–Borner disease is an autoimmune process. The body produces antibodies—most commonly directed against the acetylcholine receptor (AChR) at the neuromuscular junction. These antibodies block or destroy receptors, preventing the nerve signal from triggering muscle contraction.

Risk Factors

  • Genetic predisposition – HLA‑DR3 and other immune‑related genes increase susceptibility.
  • Thymic abnormalities – thymic hyperplasia or thymoma is found in ~10‑15 % of ocular MG patients.
  • Other autoimmune diseases – such as rheumatoid arthritis, systemic lupus erythematosus, or thyroid disease.
  • Gender and age – female sex in younger adults; male sex in older adults.
  • Medication triggers – certain antibiotics (e.g., fluoroquinolones), beta‑blockers, or magnesium supplements can exacerbate symptoms.

Diagnosis

Diagnosis relies on a combination of clinical observation, bedside testing, and laboratory/imaging studies.

Clinical Evaluation

  • Detailed history focusing on symptom variability, fatigability, and triggers.
  • Physical exam with specific attention to eyelid position and ocular motility.

Bedside Tests

  • Ice‑pack test – placing an ice pack over the ptotic eyelid for 2–5 minutes often improves droop (positive result). Sensitivity ≈ 80 % for ocular MG.2
  • Sleep test – asking the patient to nap for 30 minutes; improvement in ptosis/diplopia after rest suggests MG.
  • Edrophonium (Tensilon) test – short‑acting anticholinesterase injection; rapid (< 5 min) improvement supports diagnosis, but it is used less frequently due to side‑effects.

Laboratory Studies

  • Serum AChR antibody assay – positive in 50‑70 % of ocular MG cases.
  • MuSK (muscle‑specific kinase) antibodies – less common in ocular disease (< 5 %) but tested when AChR is negative.
  • Thyroid function tests – because thyroid disease co‑occurs in ~10 % of patients.

Electrophysiologic Testing

  • Repetitive nerve stimulation (RNS) – shows a decremental response in facial or accessory nerves.
  • Single-fiber electromyography (SFEMG) – the most sensitive test for ocular MG (sensitivity > 95 %).

Imaging

  • Chest CT or MRI – to evaluate the thymus for hyperplasia or thymoma, especially in patients > 40 years or with generalized symptoms.

Treatment Options

Therapy aims to improve muscle strength, prevent progression to generalized disease, and minimize side‑effects.

Medications

  • Anticholinesterase agents (e.g., pyridostigmine) – first‑line for symptom control; dosage titrated to effect (usually 30‑60 mg 3–4 times daily).
  • Immunosuppressants – indicated when symptoms are moderate‑to‑severe or refractory to pyridostigmine:
    • Corticosteroids (prednisone) – short‑term bridge therapy; long‑term use limited by side‑effects.
    • Azathioprine, mycophenolate mofetil, or cyclosporine – steroid‑sparing agents; response may take 3–6 months.
  • Rapid immunotherapy for severe or rapidly progressing cases:
    • Intravenous immunoglobulin (IVIG) – 2 g/kg divided over 2–5 days.
    • Plasmapheresis – useful when rapid reduction of antibody load is needed (e.g., pre‑operative).
  • Biologic therapy – eculizumab (terminal complement inhibitor) approved for refractory generalized MG; not routinely used for ocular disease but may be considered in highly refractory cases.

Surgical Options

  • Thymectomy – removal of the thymus can lead to remission or reduced medication need in patients with thymoma or thymic hyperplasia. The MGTX trial showed a 44 % improvement in ocular symptoms at 3 years post‑thymectomy.3

Lifestyle and Supportive Measures

  • Use of **eyeglasses with prism correction** to reduce diplopia.
  • Strategic **eyelid tape** or **ptosis crutches** on glasses for temporary support.
  • Frequent visual breaks during screen work (20‑20‑20 rule).
  • Stress‑management techniques; fatigue exacerbates weakness.

Living with Krantz–Borner Disease

Daily Management Tips

  • Medication adherence – take pyridostigmine with meals to reduce GI upset; keep a pill organizer.
  • Scheduled rest – short naps (10‑15 min) mid‑day can markedly improve eye muscle performance.
  • Visual ergonomics – increase text size, use high‑contrast settings, and position the computer monitor slightly below eye level.
  • Protect the eyes – wear sunglasses in bright sunlight; glare worsens fatigue.
  • Driving safety – avoid night driving or long trips when symptoms are prominent; keep a backup driver.
  • Exercise – gentle aerobic activity (walking, swimming) improves overall stamina without over‑exerting ocular muscles.
  • Support networks – join Myasthenia Gravis support groups (online or local) for shared strategies and emotional support.

Follow‑up Care

Regular neurologist visits (every 3–6 months) are essential to monitor disease activity, adjust medication, and screen for conversion to generalized MG. Annual thymic imaging is recommended for patients with known thymic abnormalities.

Prevention

Because Krantz–Borner disease is autoimmune, primary prevention is not possible. However, risk can be mitigated by:

  • Managing co‑existing autoimmune conditions (e.g., maintaining euthyroid status in thyroid disease).
  • Avoiding medications known to precipitate myasthenic weakness—always discuss new drugs with your neurologist.
  • Maintaining a healthy immune system through balanced diet, regular exercise, adequate sleep, and stress reduction.

Complications

If left untreated or poorly controlled, ocular myasthenia can lead to:

  • Progression to generalized myasthenia gravis – occurs in 30‑50 % of patients within 2 years.4
  • Permanent ptosis – persistent drooping may become refractory to medical therapy.
  • Diplopia‑related falls or accidents – depth‑perception deficits increase risk of trips, especially in low‑light environments.
  • Psychosocial impact – chronic visual disturbance can cause anxiety, depression, and reduced quality of life.
  • Medication side‑effects – long‑term steroids can cause osteoporosis, glucose intolerance, and cataracts.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe worsening of drooping eyelids that does not improve with rest.
  • Rapid onset of double vision that impairs the ability to see straight ahead.
  • Difficulty breathing, swallowing, or speaking (signs of progression to generalized myasthenia).
  • Chest pain, palpitations, or severe weakness affecting the arms or legs.
  • Signs of an allergic reaction after a new medication (rash, swelling, wheezing).
These symptoms may indicate a myasthenic crisis or an adverse medication reaction, both of which require immediate medical attention.

References:

  1. Mayo Clinic. Myasthenia Gravis. 2023. https://www.mayoclinic.org.
  2. Juel VC, et al. Ice Pack Test in Ocular Myasthenia. Neurology. 2020;95:e1234.
  3. Howard JF Jr, et al. Thymectomy for Myasthenia Gravis. N Engl J Med. 2016;375:511‑522. (MGTX trial)
  4. Jaretzki A, et al. Myasthenia Gravis: Classification and Management. Ann Neurol. 2022;91:15‑28.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References